Red light therapy is now widely available both in clinics and at home—but the differences matter. Medical-grade devices used by professionals deliver higher power and deeper penetration, often ...

Since its seed round in 2023, the company has raised $17.5 million from a mix of public and private investors to fuel product development and commercialization. Bioliberty holds eight patents across ...

I spent weeks testing red light therapy devices to see if they improved wrinkles. I also spoke to dermatologists on the ...

A handful of small, early-stage clinical trials are investigating whether CAR-T therapy can improve symptoms in multiple ...

The first cell rejuvenation therapy is set to enter clinics, testing if aging cells can be reset to a younger, healthier ...

Trump administration intelligence officials are set to face a second day of questioning Thursday on Capitol Hill, as lawmakers demand answers about the war in I 'Mean Girls' star Jonathan Bennett on ...

Vision changes can happen for a number of reasons, some of which are no major cause for concern, such as dry eye or fatigue. But others are serious enough to warrant a trip to the emergency department ...

If you've ever skipped physical therapy assignments, you're not alone. A new survey suggests that as many as 75% of people in physical therapy fail to complete their exercise programs at home, ...

View post: AKC Reveals Top 5 Dog Breeds in America, and No. 1 Is a 'Great Companion for All Ages' Polly Pocket, a tiny, malnourished puppy, overcame health challenges with creative adaptation. Foster ...

All patients dosed with SPVN06 in Phase I/II trial continue to demonstrate a favorable safety profile Initial data readout for this novel gene-agnostic therapy expected in 2027 Paris, February 9, 2026 ...

The US Food and Drug Administration (FDA) has approved a Phase 1 clinical trial from Life Biosciences that aims to help certain eye cells act younger and improve vision in glaucoma and related ...

Preliminary results from the Phase 2 ArMaDa clinical trial indicate a 46% reduction in lesion growth compared to the control group after 12 months, with no serious adverse events reported across both ...